CTSS and neoplasm: Recent FDA approvals and clinical developments of tumor-specific molecular probes, including agents such as Cytalux (targeting folate receptors)8,9 and Lumicell (activated by cathepsin),10 have underscored the clinical viability of fluorescence-guided surgery.